These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 9390333

  • 1. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology.
    Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stütz A.
    Br J Dermatol; 1997 Oct; 137(4):568-76. PubMed ID: 9390333
    [Abstract] [Full Text] [Related]

  • 2. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.
    Stuetz A, Grassberger M, Meingassner JG.
    Semin Cutan Med Surg; 2001 Dec; 20(4):233-41. PubMed ID: 11770910
    [Abstract] [Full Text] [Related]

  • 3. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981.
    Neckermann G, Bavandi A, Meingassner JG.
    Br J Dermatol; 2000 Apr; 142(4):669-79. PubMed ID: 10792216
    [Abstract] [Full Text] [Related]

  • 4. Pimecrolimus: a review.
    Gupta AK, Chow M.
    J Eur Acad Dermatol Venereol; 2003 Sep; 17(5):493-503. PubMed ID: 12941081
    [Abstract] [Full Text] [Related]

  • 5. Sdz asm 981.
    Wellington K, Spencer CM.
    BioDrugs; 2000 Dec; 14(6):409-16. PubMed ID: 18034582
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis.
    Van Leent EJ, Gräber M, Thurston M, Wagenaar A, Spuls PI, Bos JD.
    Arch Dermatol; 1998 Jul; 134(7):805-9. PubMed ID: 9681343
    [Abstract] [Full Text] [Related]

  • 7. Ascomycins in dermatology.
    Paul C, Ho VC.
    Semin Cutan Med Surg; 1998 Dec; 17(4):256-9. PubMed ID: 9859912
    [Abstract] [Full Text] [Related]

  • 8. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.
    Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP.
    Br J Dermatol; 2001 Mar; 144(3):507-13. PubMed ID: 11260007
    [Abstract] [Full Text] [Related]

  • 9. Ascomycins: promising agents for the treatment of inflammatory skin diseases.
    Paul C, Graeber M, Stuetz A.
    Expert Opin Investig Drugs; 2000 Jan; 9(1):69-77. PubMed ID: 11060661
    [Abstract] [Full Text] [Related]

  • 10. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion.
    Mrowietz U, Graeber M, Bräutigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E.
    Br J Dermatol; 1998 Dec; 139(6):992-6. PubMed ID: 9990361
    [Abstract] [Full Text] [Related]

  • 11. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology.
    Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G.
    Br J Dermatol; 1999 Aug; 141(2):264-73. PubMed ID: 10468798
    [Abstract] [Full Text] [Related]

  • 12. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases.
    Mollison KW, Fey TA, Gauvin DM, Kolano RM, Sheets MP, Smith ML, Pong M, Nikolaidis NM, Lane BC, Trevillyan JM, Cannon J, Marsh K, Carter GW, Or YS, Chen YW, Hsieh GC, Luly JR.
    J Invest Dermatol; 1999 May; 112(5):729-38. PubMed ID: 10233764
    [Abstract] [Full Text] [Related]

  • 13. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
    Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schoepf E, Thestrup-Pedersen K, Van Der Valk PG, Bos JD.
    Br J Dermatol; 2001 Apr; 144(4):788-94. PubMed ID: 11298538
    [Abstract] [Full Text] [Related]

  • 14. Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.
    Mollison KW, Fey TA, Gauvin DM, Sheets MP, Smith ML, Pong M, Krause R, Miller L, Or YS, Kawai M, Wagner R, Wiedeman PE, Clark RF, Gunawardana IW, Rhoades TA, Henry CL, Tu NP, BaMaung NY, Kopecka H, Liu L, Xie Q, Lane BC, Trevillyan JM, Marsh K, Luly JR.
    Curr Pharm Des; 1998 Oct; 4(5):367-79. PubMed ID: 10197049
    [Abstract] [Full Text] [Related]

  • 15. First experience of topical SDZ ASM 981 in children with atopic dermatitis.
    Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P.
    Br J Dermatol; 2001 Apr; 144(4):781-7. PubMed ID: 11298537
    [Abstract] [Full Text] [Related]

  • 16. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner.
    Hultsch T, Müller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J.
    Arch Dermatol Res; 1998 Sep; 290(9):501-7. PubMed ID: 9808344
    [Abstract] [Full Text] [Related]

  • 17. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.
    Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH.
    Transplantation; 1997 Jul 15; 64(1):36-42. PubMed ID: 9233698
    [Abstract] [Full Text] [Related]

  • 18. [Development and pre-clinical aspects of pimecrolimus].
    Stütz A, Grassberger M, Meingassner JG.
    Hautarzt; 2003 May 15; 54(5):405-12. PubMed ID: 12719859
    [Abstract] [Full Text] [Related]

  • 19. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
    Wellington K, Jarvis B.
    Drugs; 2002 May 15; 62(5):817-40. PubMed ID: 11929333
    [Abstract] [Full Text] [Related]

  • 20. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge.
    Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, de Cuyper C, Ortonne JP.
    Contact Dermatitis; 2000 Jun 15; 42(6):349-50. PubMed ID: 10871099
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.